Certara Inc (CERT) Stock Price, Quote & News

Company Profile

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharm...

Industry: Health Information Services

Sector: Healthcare

Phone: 415 237 8272

Website: www.certara.com

Address:

4 Radnor Corporate Center, Suite 350, Radnor, United States

DonCorleone77 Mar. 7 at 5:18 PM

$CERT Certara price target lowered to $10 from $15 at UBS UBS lowered the firm's price target on Certara to $10 from $15 and keeps a Buy rating on the shares. The firm says the company's Q4 results and 2026 guidance challenge the Buy thesis on the shares. Certara reported a Q4 services miss and deceleration in software bookings, the analyst tells investors in a research note. However, UBS believes the company remains "uniquely positioned" in model-informed drug development.

0 · Reply

BillionerOfKing Mar. 5 at 12:03 AM

$CERT Current Stock Price: $7.35 Contracts to trade: $7.5 CERT Mar 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 49% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

StockNews_Live Mar. 3 at 1:00 PM

$CERT Certara, Inc. announced its Simcyp Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S. FDA in lieu of clinical studies to support the new drug appl…

0 · Reply

OfficialStocktwitsUser Feb. 27 at 2:47 AM

$CERT RSI: 33.33, MACD: -0.6142 Vol: 0.80, MA20: 7.17, MA50: 8.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

briefingcom Feb. 26 at 1:26 PM

$CERT: Certara misses by $0.02, reports revs in-line; guides FY26 EPS below consensus, revs below consensus https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260226060523CERT&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

BigDaddyCapital Feb. 26 at 12:03 PM

$CERT company bought back shares this quarter

0 · Reply

StocktwitsEarnings Feb. 26 at 11:31 AM

$CERT Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.04 down -200.00% YoY • Reported revenue of $103.65M up 3.28% YoY • Certara expects full year 2026 revenue growth of 0-4%, an adjusted EBITDA margin of approximately 30-32%, and adjusted diluted EPS in the range of $0.44-$0.48.

0 · Reply

TradeStrider Feb. 18 at 10:13 AM

$CERT Auto logistics platform benefiting from digital adoption.

0 · Reply

Estimize Feb. 10 at 9:00 PM

Wall St is expecting 0.14 EPS for $CERT Q1 [Reporting 05/11 AMC] http://www.estimize.com/intro/cert?chart=historical&metric_name=eps&utm_co

0 · Reply

LongTermLens Feb. 4 at 2:18 PM

$CERT is a provider of enterprise software for identity and access management; it operates in the competitive cybersecurity market and must demonstrate consistent growth.

1 · Reply

Certara, Inc. (CERT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 9, 2026, 10:28 AM EDT - 8 days ago

Certara, Inc. (CERT) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 3, 2026, 6:12 PM EST - 14 days ago

Certara, Inc. (CERT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 8:00 AM EST - 14 days ago

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

Mar 2, 2026, 7:20 AM EST - 16 days ago

Touchstone Small Cap Fund Q4 2025 Portfolio Review

CCC DV GTES HAE NEU RVLV WTM

Feb 27, 2026, 8:30 AM EST - 18 days ago

Certara to Participate in Upcoming Investor Conferences

Feb 26, 2026, 1:37 PM EST - 19 days ago

Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 6:00 AM EST - 20 days ago

Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance

Feb 17, 2026, 9:27 AM EST - 4 weeks ago

The London Company Small Cap Q4 2025 Performance And Trades

AWI CCC DV GTES HAE NEU RVLV

Feb 3, 2026, 6:23 AM EST - 6 weeks ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

VVOS ZLAB

Jan 29, 2026, 8:30 AM EST - 6 weeks ago

Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025

Jan 27, 2026, 10:10 AM EST - 7 weeks ago

Wasatch Core Growth Fund Q4 2025 Performance Review

FN FOUR RBC TREX XPEL

Jan 26, 2026, 1:32 PM EST - 7 weeks ago

Cerrado Gold Inc. (CERT:CA) Discusses Purported Unfavourable Opinion of Environmental Impact Assessment for Lagoa Salgada Project Transcript

Dec 31, 2025, 10:57 AM EST - 2 months ago

Tax-related selling could set up these 11 stocks for big gains early in 2026

CNH CNS COTY FRSH GOGO JJSF KNTK

Dec 11, 2025, 6:00 AM EST - 3 months ago

Certara Appoints Jon Resnick as Chief Executive Officer

Dec 1, 2025, 5:13 PM EST - 3 months ago

Cerrado Gold Inc. (CERT:CA) Q3 2025 Earnings Call Transcript

Nov 27, 2025, 9:30 AM EST - 3 months ago

Touchstone Small Company Fund Q3 2025 Performance Review

APLE CIEN EME GPOR HAE KLIC MMS

Nov 18, 2025, 4:48 PM EST - 4 months ago

Certara, Inc. (CERT) Presents at Stephens Annual Investment Conference 2025 Transcript

Nov 18, 2025, 7:38 AM EST - 4 months ago

Certara, Inc. (CERT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 6, 2025, 8:56 PM EST - 4 months ago

Certara, Inc. (CERT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:15 PM EST - 4 months ago

Certara Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 8:00 AM EST - 4 months ago

Certara Automates Scientific Workflows with Phoenix® Cloud

Oct 30, 2025, 4:15 PM EDT - 4 months ago

Certara Expands Biosimulation Market with AI-Driven QSP Platform

Oct 20, 2025, 8:00 AM EDT - 5 months ago

Certara Scientists are Among the Topmost Cited Biopharma Researchers

Oct 15, 2025, 5:55 PM EDT - 5 months ago

Why Investors Should Consider Certara Again

Oct 10, 2025, 8:00 AM EDT - 5 months ago

Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

Sep 23, 2025, 6:34 PM EDT - 6 months ago

Final Trade: CERT, GDX, IWM, MPC

GDX IWM MPC

Sep 10, 2025, 2:40 PM EDT - 6 months ago

Certara, Inc. (CERT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:21 PM EDT - 6 months ago

Certara, Inc. (CERT) Presents At Baird Global Healthcare Conference 2025 (Transcript)

Sep 4, 2025, 8:00 AM EDT - 6 months ago

Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster

Aug 25, 2025, 1:32 PM EDT - 7 months ago

Cerrado Gold Inc. (CRDOF) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 10:24 PM EDT - 7 months ago

Certara, Inc. (CERT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:15 PM EDT - 7 months ago

Certara Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 2:00 AM EDT - 8 months ago

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling

Jul 31, 2025, 4:15 PM EDT - 8 months ago

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

Jul 11, 2025, 3:09 AM EDT - 8 months ago

Certara: Ideally Positioned To Benefit From IT Innovation In Life Sciences

Jul 9, 2025, 4:15 PM EDT - 8 months ago

Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025

Jul 8, 2025, 8:00 AM EDT - 9 months ago

Certara Announces Expansion of Clinical Technology Collaboration with Merck

May 5, 2025, 7:22 PM EDT - 11 months ago

Certara, Inc. (CERT) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:15 PM EDT - 11 months ago

Certara Reports First Quarter 2025 Financial Results

Apr 14, 2025, 2:08 PM EDT - 1 year ago

Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report

Apr 14, 2025, 8:15 AM EDT - 1 year ago

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Apr 11, 2025, 1:15 PM EDT - 1 year ago

Buy Certara After The FDA Announcement

Apr 11, 2025, 10:44 AM EDT - 1 year ago

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

CRL SLP

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

Mar 5, 2025, 4:15 PM EST - 1 year ago

Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

Feb 26, 2025, 8:03 PM EST - 1 year ago

Certara, Inc. (CERT) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:15 PM EST - 1 year ago

Certara Reports Fourth Quarter 2024 Financial Results

Jan 29, 2025, 4:15 PM EST - 1 year ago

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

Jan 15, 2025, 7:55 AM EST - 1 year ago

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

DonCorleone77 Mar. 7 at 5:18 PM

0 · Reply

BillionerOfKing Mar. 5 at 12:03 AM

0 · Reply

StockNews_Live Mar. 3 at 1:00 PM

0 · Reply

OfficialStocktwitsUser Feb. 27 at 2:47 AM

0 · Reply

briefingcom Feb. 26 at 1:26 PM

0 · Reply

BigDaddyCapital Feb. 26 at 12:03 PM

$CERT company bought back shares this quarter

0 · Reply

StocktwitsEarnings Feb. 26 at 11:31 AM

0 · Reply

TradeStrider Feb. 18 at 10:13 AM

$CERT Auto logistics platform benefiting from digital adoption.

0 · Reply

Estimize Feb. 10 at 9:00 PM

Wall St is expecting 0.14 EPS for $CERT Q1 [Reporting 05/11 AMC] http://www.estimize.com/intro/cert?chart=historical&metric_name=eps&utm_co

0 · Reply

LongTermLens Feb. 4 at 2:18 PM

$CERT is a provider of enterprise software for identity and access management; it operates in the competitive cybersecurity market and must demonstrate consistent growth.

1 · Reply

BigDaddyCapital Feb. 2 at 8:46 PM

$CERT biggest PoS company on the market

0 · Reply

Crom5775 Jan. 27 at 1:20 PM

$CERT Keeping above its SymmetricalTriangle breakout. 50 day moving has started to curl up. Looks like a bull flag is setting up.

0 · Reply

BillionerOfKing Jan. 21 at 3:01 AM

$CERT Current Stock Price: $9.50 Contracts to trade: $10 CERT Feb 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 36% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

stockingu Jan. 14 at 3:01 PM

$PRSU, $CERT , $CRWV , $CRCL

0 · Reply

OfficialStocktwitsUser Jan. 13 at 8:24 PM

$CERT RSI: 51.55, MACD: 0.0287 Vol: 0.30, MA20: 9.05, MA50: 9.17 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ItoLemmaI Dec. 26 at 3:51 PM

$CERT Expectations are recalibrating toward pragmatic delivery instead of lofty projections. Efficiency initiatives must translate into measurable productivity. Overextension would degrade optionality during downturns. The trajectory strengthens as results compound visibly.

0 · Reply

JarvisFlow Dec. 18 at 5:42 PM

Morgan Stanley has updated their rating for Certara ( $CERT ) to Equal-Weight with a price target of 12.

0 · Reply

JarvisFlow Dec. 15 at 8:57 PM

Barclays has updated their rating for Certara ( $CERT ) to Overweight with a price target of 13.

0 · Reply

Estimize Dec. 15 at 12:09 PM

Wall St is expecting 0.11 EPS for $CERT Q4 [Reporting 02/26 AMC] http://www.estimize.com/intro/cert?chart=historical&metric_name=eps&utm_co

0 · Reply

Market Cap	1.06B
Revenue (ttm)	418.84M
Net Income (ttm)	-1.60M
EPS (ttm)	N/A
PE Ratio	24.63
Forward PE	22.42
Profit Margin	-0.38%
Debt to Equity Ratio	0.28

Volume	3,556,500
Avg Vol	2,942,064
Day's Range	N/A - N/A
Shares Out	159.14M
Stochastic %K	26%
Beta	1.50
Analysts	Sell
Price Target	$9.48